Ph 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination With Cytarabine With Subsequent Phase 2 Cohorts for Subjects With Relapsed/Refractory Acute AML and MDS

Trial Profile

Ph 1b Dose Escalation Study of OXi4503 as a Single Agent and in Combination With Cytarabine With Subsequent Phase 2 Cohorts for Subjects With Relapsed/Refractory Acute AML and MDS

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Sep 2017

At a glance

  • Drugs Combretastatin A1 phosphate (Primary) ; Cytarabine
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Mateon Therapeutics
  • Most Recent Events

    • 31 Jul 2017 Preliminary data from the fifth dose cohort of this trial published in a Mateon Therapeutics media release.
    • 12 Jun 2017 Results from the fourth cohort published in a Mateon Therapeutics media release.
    • 07 Jun 2017 According to a Mateon Therapeutics media release, the US FDA has granted Fast Track designation to OXi4503 for the treatment of acute myeloid leukemia (AML) based on promising results from the initial cohorts in this trial. Completion of the fifth patient cohort is expected by the end of this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top